Due to health issues, this site is no longer maintained and will be shut down shortly.

CLLS Cellectis SA ADRs

Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:ALCLS.

$1.99  -0.05 (-2.45%)
As of 03/27/2023 11:52:27 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  03/25/2015
Outstanding shares:  55,583,768
Average volume:  83,726
Market cap:   $113,390,887
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BWFKZT2
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy